Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-653 TMS crossover study in healthy volunteers with open-label ketamine comparator
NL-OMON47989Completed
- Sponsor
- Takeda
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of osavampator in treatment-resistant depression (TRD) and major depressive disorder (MDD) (4 arms), sponsored by Takeda. Primary endpoints: Change in TMS-evoked motor evoked potential amplitude after TAK-653 versus placebo and Change in resting motor threshold after TAK-653 versus placebo. Started Jan 2019; status: completed.
02
Drugs
osavampator
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON47989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47989.